Product meets AWMSG exclusion criteria due to NICE appraisals TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer and TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Product meets AWMSG exclusion criteria due to NICE appraisals TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer and ID3755: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593)
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2016 AND FEBRUARY 2018. Refer to TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens and TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only.
Paclitaxel albumin (Abraxane) monotherapy is recommended as an option for use within NHS Wales for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for who standard, anthracycline containing therapy is not indicated. AWMSG is of the opinion that paclitaxel albumin (Abraxane) is not suitable for shared care within NHS Wales. Clinicians should follow the National Institute for Health and Clinical Excellence (NICE) Guidelines CG81…
Oral vinorelbine (Navelbine) is recommended for use within NHS Wales as a single agent (in line with current NICE recommendations for IV vinorelbine), for the treatment of advanced breast cancer stage III and IV relapsing after or refractory to an anthracycline-containing regimen. Oral vinorelbine (Navelbine) should only be initiated by specialists experienced in the treatment of breast cancer. Oral vinorelbine (Navelbine) should not presently be recommended for shared care.
Product meets AWMSG exclusion criteria due to NICE appraisal TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Product meets AWMSG exclusion criteria due to NICE appraisal TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Product meets AWMSG exclusion criteria due to NICE appraisal TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (replaced TA295)